Loading...
•
Sep 30, 2024
Abbott Q3 2024 Earnings Report
Abbott's Q3 2024 performance was driven by strong underlying base business, with sales reaching $10.6 billion and organic sales growth of 8.2 percent.
Key Takeaways
Abbott's Q3 2024 earnings showcased a robust performance, with sales of $10.6 billion driven by strong underlying base business performance. The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.21. Abbott has raised the midpoint of its full-year EPS guidance range.
Sales of $10.6 billion driven by strong underlying base business performance.
Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent, led by double-digit growth in Medical Devices.
Maintained full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales.
Board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares.
Abbott
Abbott
Abbott Revenue by Segment
Abbott Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMedical Devices Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.34 to $3.40 and projects adjusted diluted earnings per share of $4.64 to $4.70.
Positive Outlook
- Full-year 2024 diluted EPS on a GAAP basis of $3.34 to $3.40.
- Adjusted diluted EPS of $4.64 to $4.70 for the full-year 2024, which represents an increase at the midpoint of the guidance range.
- Fourth-quarter 2024 diluted earnings per share under GAAP of $0.96 to $1.02.
- Adjusted diluted earnings per share would be $1.31 to $1.37 for the fourth quarter 2024.
- Maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income